NasdaqGS - Delayed Quote USD
Guardant Health, Inc. (GH)
114.04 +3.56 (+3.22%)
At close: January 30 at 4:00:03 PM EST
114.03 -0.01 (-0.01%)
After hours: January 30 at 7:40:18 PM EST
Chart Range Bar
Loading chart for GH
- Previous Close
110.48 - Open
111.59 - Bid 113.82 x 300
- Ask 114.30 x 600
- Day's Range
108.74 - 114.97 - 52 Week Range
34.88 - 120.74 - Volume
1,612,082 - Avg. Volume
2,258,309 - Market Cap (intraday)
14.811B - Beta (5Y Monthly) 1.59
- PE Ratio (TTM)
-- - EPS (TTM)
-3.32 - Earnings Date Feb 19, 2026
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
125.24
Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, and data sets in the United States and internationally. The company provides precision oncology testing services comprising Guardant360, a panel of genetic tests; Guardant360 LDT that measures 730+ genes and supports all guideline-recommended biomarkers; Guardant360 CDx Test, a liquid biopsy test; Guardant360 Response Test, a blood-only liquid biopsy; Guardant360 TissueNext Test, a tissue-based test with AI-powered PD-L1 detection; GuardantINFINITY Test that provides insights into the complexities of tumor molecular profiles and immune response to advance cancer research and therapy development; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI blood test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It also offers Shield Test; Guardant Reveal Test for adjuvant treatment and surveillance settings in early-stage cancer patients; and Smart Liquid Biopsy Platform. In addition, the company provides development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kit fulfillment and delivery of Shield screening tests. The company was incorporated in 2011 and is headquartered in Palo Alto, California.
guardanthealth.com1,999
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GH
View More
Performance Overview: GH
Trailing total returns as of 1/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
GH
11.65%
S&P 500 (^GSPC)
1.37%
1-Year Return
GH
128.35%
S&P 500 (^GSPC)
14.29%
3-Year Return
GH
269.42%
S&P 500 (^GSPC)
72.71%
5-Year Return
GH
26.66%
S&P 500 (^GSPC)
86.82%
Earnings Trends: GH
View MoreAnalyst Insights: GH
View MoreStatistics: GH
View MoreValuation Measures
As of 1/29/2026
Market Cap
14.35B
Enterprise Value
15.09B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
15.20
Price/Book (mrq)
--
Enterprise Value/Revenue
16.72
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-44.18%
Return on Assets (ttm)
-19.64%
Return on Equity (ttm)
--
Revenue (ttm)
902.57M
Net Income Avi to Common (ttm)
-398.79M
Diluted EPS (ttm)
-3.32
Balance Sheet and Cash Flow
Total Cash (mrq)
580.01M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-24.38M
Compare To: GH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Company Insights: GH
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected. Learn more
Dividend Score
The distribution of earnings a company pays back to its shareholders based off the company’s profits. Usually paid out on a quarterly basis in the form of cash or additional stocks.
Hiring Score
A company’s hiring trends in key indicators can indicate how well the company is doing in terms of growing the company and where they are currently prioritizing.
Insider Sentiment Score
Vicker’s Insider Sentiment provides insights into trades made by insiders. This can be used to gain valuable insights and as a reflection of the prospect of the company based on insider trading.
Research Reports: GH
View MoreGuardant Health Earnings: Soaring Shield Sales Drive Higher Full-Year Guidance; Raising Fair Value
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
RatingPrice TargetDaily – Vickers Top Buyers & Sellers for 12/18/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Daily – Vickers Top Buyers & Sellers for 12/09/2025
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Guardant Health Earnings: Soaring Shield Sales Drive Higher Full-Year Guidance; Raising Fair Value
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company offers Guardant360 LDT, a liquid biopsy test for treatment selection in advanced-stage cancer, Guardant360 CDx, an FDA-approved companion diagnostic for several targeted therapies, and Guardant Omni, a broader gene panel for immuno-oncology research. In 2021, Guardant launched Reveal, a tumor-agnostic molecular residual disease test. In 2024, the company received US FDA approval for Shield, a liquid biopsy for colorectal cancer screening. Additionally, Guardant offers research development services such as regulatory approval consultancy and clinical trial referrals.
RatingPrice Target